Literature DB >> 12222874

Progress and challenges in viral vector-mediated gene transfer to the brain.

Pedro R Lowenstein1, Maria G Castro.   

Abstract

Gene transfer into the brain allows the manipulation of transgene expression in both time and space. Recently developed gene transfer technologies allow transgenes to be expressed in any anatomically, biochemically or functionally distinct group of brain cells. Gene transfer has been used to alter the expression of neurotransmitter receptors, ion channels, signaling proteins, neuronal growth, differentiation and survival factors, and thus to modify brain anatomy, neuron physiology, behavior and pathology. However, challenges remain in making gene therapy a more widespread tool for the treatment of neurological disease. We have identified the following as areas needing development: access and delivery of viral vectors to the brain; diffusion of viral vectors and transgenes throughout large areas of brain tissue; viral vector side effects and toxicity, inflammatory and immune responses to vectors; long-term stable transgene expression; cell type-specific expression of transgenes; and the ability of the experimenter or physician to switch transgene expression 'on' and 'off' at will. In the last year, neuro-gene therapy has shown that brain defects in experimental disease models can be prevented and corrected, and that viral vectors and encoded transgenes can be made to diffuse over larger brain areas. In addition, the cause of vector-induced inflammation and immune responses have begun to be elucidated, so that rational approaches can be developed to avoid these complications. Further improvements in viral vectors will facilitate clinical trials in the near future.

Entities:  

Mesh:

Year:  2002        PMID: 12222874

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  14 in total

Review 1.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

2.  Lentiviral vector mediates exogenous gene expression in adult rat DRG following peripheral nerve remote delivery.

Authors:  Ping Yang
Journal:  J Mol Neurosci       Date:  2012-02-09       Impact factor: 3.444

Review 3.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

4.  5-HT1B autoreceptors differentially modulate the expression of conditioned fear in a circuit-specific manner.

Authors:  Y Liu; M A Kelly; T J Sexton; J F Neumaier
Journal:  Neuroscience       Date:  2015-04-20       Impact factor: 3.590

5.  Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors.

Authors:  Jeffrey M Zirger; Chunyan Liu; Carlos Barcia; Maria G Castro; Pedro R Lowenstein
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

Review 6.  Gene activation and protein expression following ischaemic stroke: strategies towards neuroprotection.

Authors:  M Slevin; J Krupinski; P Kumar; J Gaffney; S Kumar
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

7.  Functional applications of novel Semliki Forest virus vectors are limited by vector toxicity in cultures of primary neurons in vitro and in the substantia nigra in vivo.

Authors:  Paul Lingor; Ulrike Schöll; Mathias Bähr; Sebastian Kügler
Journal:  Exp Brain Res       Date:  2004-10-20       Impact factor: 1.972

Review 8.  Gene therapy for pituitary tumors.

Authors:  Adriana Seilicovich; Daniel Pisera; Sandra A Sciascia; Marianela Candolfi; Mariana Puntel; Weidong Xiong; Gabriela Jaita; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

9.  Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression.

Authors:  Daniel Stone; Weidong Xiong; Judith C Williams; Anne David; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454

Review 10.  Recent advances in the pharmacology of neurological gene therapy.

Authors:  Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Curr Opin Pharmacol       Date:  2004-02       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.